27 февраля 2017, 17:06

Америка сегодня. Заказы на товары длительного пользования и индекс незавершенных продаж.

В заказах на товары длительного пользования ожидается новый восходящий цикл:

Рост в заказах за последний месяц аналитиками оценивается на отметке 2%:

Также продолжение роста происходит и в данных по рынку недвижимости. Новый показатель незавершенных продаж оценивается отдельными аналитическими агентствами на уровне 0.8%:

Все новости:

Америка сегодня. Заказы на товары длительного пользования и индекс незавершенных продаж.

Данные: DTC News, Briefing, Interactive, Economics, Public Sources

американский рынок аналитика NYSE NASDAQ AMEX day trading daytrader DayTraderClub OTCBB проп-трейдинг проп-компании проп TOS TWS акции

Daytrader

Польша

397

5 263

с 25 ноября 2011

120 Комментариев

Daytrader
27 февраля 2017, 17:08
Main Street Capital downgraded to Outperform from Strong Buy at Raymond James (37.48)
0

	Main Street Capital downgraded to Outperform from Strong Buy at Raymond James (37.48)

Daytrader

27 февраля 2017, 17:11

	Exelixis and Bristol-Myers Squibb (BMY) enter into clinical development collaboration to evaluate CABOMETYX with Opdivo (21.69)The co and Bristol-Myers Squibb Company (BMY) announced the companies have entered into a clinical development collaboration to evaluate CABOMETYX (cabozantinib), Exelixis' small molecule inhibitor of receptor tyrosine kinases, with Opdivo (nivolumab), Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor, either alone or in combination with Yervoy (ipilimumab). The clinical development program, which will be co-funded by the companies, is expected to include a phase 3 pivotal trial in first-line renal cell carcinoma, with additional trials planned in bladder cancer, hepatocellular carcinoma (HCC), and potentially other tumor types.

Exelixis and Bristol-Myers Squibb (BMY) enter into clinical development collaboration to evaluate CABOMETYX with Opdivo (21.69)The co and Bristol-Myers Squibb Company (BMY) announced the companies have entered into a clinical development collaboration to evaluate CABOMETYX (cabozantinib), Exelixis' small molecule inhibitor of receptor tyrosine kinases, with Opdivo (nivolumab), Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor, either alone or in combination with Yervoy (ipilimumab). The clinical development program, which will be co-funded by the companies, is expected to include a phase 3 pivotal trial in first-line renal cell carcinoma, with additional trials planned in bladder cancer, hepatocellular carcinoma (HCC), and potentially other tumor types.

Daytrader
27 февраля 2017, 17:11

Heron Therapeutics initiated with a Buy at Needham; tgt $28 (13.90)
0

	Heron Therapeutics initiated with a Buy at Needham; tgt $28 (13.90)

Daytrader

27 февраля 2017, 17:11

	PostNL shares down 7% overseas following Q4 results & FY17 outlook (4.59) Q4 Profit for the period of €84 million (Q4 2015: €101 million); Revenue Q4 2016 at €955 million (Q4 2015: €1,007 million). Outlook: Outlook 2017 and increased ambition 2020: Accelerating growth in global e-commerce will fuel stronger growth in PostNL's parcels business and cross-border activities. €115 million additional cost savings in anticipation of mail volume decline. Accelerated transformation is expected to deliver improved results for 2020; ambition underlying cash operating income 2020 increased to between €310 million — €380 million (previously €285 million — €355 million). Outlook underlying cash operating income 2017 adjusted to €220 million — €260 million, reflecting impact from additional implementation costs related to increased cost saving plans. Dividend: «In view thereof, PostNL will recommend to the Annual General Meeting of Shareholders the payment of an election dividend of €0.12 per ordinary share over FY 2016. This represents a pay out ratio of 2/3rd of 75% of the underlying net cash income, which amounted to €101 million in 2016. The dividend of €0.12 will be paid, at the shareholder's election, either in ordinary PostNL shares or in cash.»

PostNL shares down 7% overseas following Q4 results & FY17 outlook (4.59)

Q4 Profit for the period of €84 million (Q4 2015: €101 million); Revenue Q4 2016 at €955 million (Q4 2015: €1,007 million).
Outlook: Outlook 2017 and increased ambition 2020: Accelerating growth in global e-commerce will fuel stronger growth in PostNL's parcels business and cross-border activities. €115 million additional cost savings in anticipation of mail volume decline. Accelerated transformation is expected to deliver improved results for 2020; ambition underlying cash operating income 2020 increased to between €310 million — €380 million (previously €285 million — €355 million). Outlook underlying cash operating income 2017 adjusted to €220 million — €260 million, reflecting impact from additional implementation costs related to increased cost saving plans.
Dividend: «In view thereof, PostNL will recommend to the Annual General Meeting of Shareholders the payment of an election dividend of €0.12 per ordinary share over FY 2016. This represents a pay out ratio of 2/3rd of 75% of the underlying net cash income, which amounted to €101 million in 2016. The dividend of €0.12 will be paid, at the shareholder's election, either in ordinary PostNL shares or in cash.»

Читайте на SMART-LAB:

Инвестиции в индустриальную недвижимость с выплатами: новый фонд

Т-Инвестиции запускают новый фонд, позволяющий зарабатывать на аренде складских комплексов класса А. Это возможность диверсифицировать свой портфель и получать регулярный доход с...

Т-Инвестиции

02.04.2026

Ипотека без опасности

Секьюритизация ипотечных кредитов – один из ключевых бизнесов ДОМ.PФ За последнее десятилетие объём выпусков ипотечных облигаций при нашем участии превысил 3,6 трлн рублей. Как это...

ДОМ.РФ

02.04.2026

Акции как защита от инфляции – работает ли это на дистанции?

В теории акции часто называют естественной защитой от инфляции. Логика понятна – если в экономике растут цены, то на длинном горизонте растут и номинальные выручка, EBITDA, прибыль, а значит и...

Газпромбанк

02.04.2026

Ви.ру МСФО 2025 г. - хороший отчет, хороший гайденс

Компания Ви.ру (Всеинструменты) отчиталась за 2025 год по МСФО. Выручка за год выросла на 7,5% до 183 млрд руб., в 4-м квартале выручка снизилась на 2% до 48,5 млрд руб. Чистая прибыль...